Loading...
Loading...
Stifel Nicolaus maintained Alexion Pharmaceuticals
ALXN with a Buy rating and lowered the price target from $125.00 to $118.00.
Stifel Nicolaus said, "Alexion posted FY12 top/bottom-line growth of >40% in the 5th consecutive year of Soliris commercialization – growth that appears readily achievable once again in FY13. While acknowledging the timing of European aHUS reimbursements and incremental data/news flow (mostly 2H13-weighted) is likely limiting the sense of urgency here, we remain hard-pressed to find a company with better fundamentals. We're taking our previously Street-high FY13 and forward-year estimates down marginally, reducing our target price to $118 (previously $125), and remaining Buy-rated."
Alexion Pharmaceuticals closed at $87.63 on Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in